EKSO BIONICS HOLDINGS (EKSO) Company Report

EKSO Bionics Holdings, Inc. entered into a Securities Purchase Agreement on January 20, 2026, to issue and sell 5,852 shares of Series B Convertible Preferred Stock and other securities to various purchasers.
As of January 21, 2026, the company's authorized capital stock included 141,429,000 shares of common stock and 10,000,000 shares of preferred stock, with 3,563,152 shares of common stock issued and outstanding and no preferred stock issued and outstanding prior to this agreement.
The company has committed to promptly apply for the listing of the Conversion Shares and Warrant Shares on Nasdaq and to use commercially reasonable efforts to maintain the listing of its Common Stock.
EKSO Bionics Holdings, Inc. will not receive any proceeds from the sale of common stock by selling securityholders under the related prospectus.

Jan 22, 2026, 9:57 PM

8-K

EKSO Bionics Holdings, Inc. and Applied Digital Propose Business Combination to Launch ChronoScale

EKSO

M&A

New Projects/Investments

EKSO Bionics Holdings, Inc. and Applied Digital have entered into a non-binding term sheet for a proposed business combination.
The transaction involves Applied Digital's cloud computing business, Applied Digital Cloud, combining with EKSO to form ChronoScale Corporation, an accelerated compute platform for AI workloads.
Upon closing, Applied Digital is expected to own approximately 97% of ChronoScale, with EKSO's existing stockholders holding 3%.
EKSO plans to continue exploring the sale of all or substantially all of its current business.
The proposed transaction is anticipated to close in the first half of 2026.

Dec 29, 2025, 10:03 PM

8-K

Ekso Bionics Holdings, Inc. Grants Executive Equity Awards and Enters Severance Agreements

EKSO

Executive Compensation

Management Change

M&A

On November 5, 2025, Ekso Bionics Holdings, Inc. granted equity awards to executives Scott Davis, Jerome Wong, and Jason Jones.
These awards included fully vested restricted stock units (RSUs) and phantom performance-based restricted stock units (Phantom PSUs).
The Phantom PSUs, which are cash-settled, vest upon a Change in Control and achievement of a Stock Price of at least $7.50 within a five-year period.
The company also entered into Change in Control and Severance Agreements with these executives on November 5, 2025.
For a "Qualifying CIC Termination," Mr. Davis is eligible for 18 months of salary severance and COBRA coverage, while other executives receive 9 months of salary severance and COBRA coverage, plus full vesting acceleration for time-based equity awards.

Nov 7, 2025, 10:03 PM

8-K

Ekso Bionics Announces $3.2 Million Registered Direct Offering

EKSO

On October 28, 2025, Ekso Bionics Holdings, Inc. entered into a securities purchase agreement for a registered direct offering of 769,490 shares of common stock at $4.81 per share.
The offering is anticipated to close around October 30, 2025, and is expected to generate approximately $3.2 million in net proceeds.
The company plans to utilize the net proceeds for general corporate purposes, which may include research and development activities, selling, general and administrative costs, strategic initiatives, and working capital needs.
Lake Street Capital Markets, LLC, acting as the placement agent, will receive a cash fee of 6% of the gross proceeds and a warrant to purchase 15,389 shares of common stock at an exercise price of $4.81 per share.

Oct 30, 2025, 10:35 AM

8-K

Ekso Bionics Announces Registered Direct Offering

EKSO

New Projects/Investments

Ekso Bionics Holdings, Inc. entered into a definitive agreement on October 28, 2025, to sell 769,490 shares of common stock at a purchase price of $4.81 per share in a registered direct offering.
The offering is expected to generate gross proceeds of $3.7 million for the company.
The closing of the offering is anticipated around October 30, 2025.
The company intends to use the net proceeds for general corporate purposes, including research and development activities, strategic initiatives, and working capital needs.

Oct 29, 2025, 12:00 PM

Press Release

EKSO Bionics Reports Q3 2025 Financial Results and Explores Strategic Transactions

EKSO

Earnings

Revenue Acceleration/Inflection

M&A

Ekso Bionics Holdings, Inc. reported Q3 2025 revenue of $4.2 million, representing a 105% sequential rebound from Q2 2025 and a 2% year-over-year increase.
The company's gross margin increased to 60.3% in Q3 2025, an improvement of 680 basis points year-over-year and 2,050 basis points sequentially.
Net loss improved by 31% year-over-year and 48% sequentially to $1.4 million, or $0.54 per basic and diluted share, for Q3 2025.
As of September 30, 2025, Ekso Bionics held $2.7 million in cash.
The company announced it is exploring one or more strategic transactions, which may involve acquiring a new line of business or selling all or substantially all of its current business.

Oct 28, 2025, 8:05 PM

8-K

Ekso Bionics Reports Q3 2025 Financial Results and Strategic Review

EKSO

Earnings

M&A

Revenue Acceleration/Inflection

Ekso Bionics reported revenue of $4.2 million for the third quarter of 2025, representing a 105% sequential increase from Q2 2025 and a 2% year-over-year growth.
The company's gross margin for Q3 2025 increased to 60.3%, an improvement of 2,050 basis points sequentially and 680 basis points year-over-year.
Net loss improved 48% sequentially and 31% year-over-year to $1.4 million for the third quarter of 2025.
Ekso Bionics is exploring one or more strategic transactions, which could include acquiring a line of business in a different industry or selling all or substantially all of its current business.

Oct 28, 2025, 8:05 PM

Press Release

EKSO Bionics Reports Q3 2025 Strategic Developments

EKSO

New Projects/Investments

Revenue Acceleration/Inflection

CMS approved a lump sum reimbursement of $91,032 for Ekso Indego Personal, effective April 1, 2024. The first claim was approved in Q2 2024, with significant pipeline growth reported in Q2 2025.
The company is scaling its Personal Health go-to-market strategy through key distribution partnerships, including National Seating & Mobility (Q1 2025) and Bionic P&O (Q2 2025), and launched Ekso University in Q2 2025 to provide continuing education for neurological physical therapists.
EKSO is advancing AI innovation by developing a foundation model for human motion, leveraging ~350,000 patient sessions and 15 million+ step-by-step data points, and has been accepted into the NVIDIA Connect Program.
The company maintains a strong global presence with over 500 centers and 1,000 devices deployed worldwide for neuro-rehabilitation, holding FDA clearance for multiple indications.

Oct 28, 2025, 8:00 PM

Presentation

Ekso Bionics Holdings, Inc. Secures New $2.0 Million Loan and Terminates Previous Debt

EKSO

Debt Issuance

New Projects/Investments

Ekso Bionics Holdings, Inc. (EKSO) entered into a Secured Promissory Note and Security Agreement with B. Riley Commercial Capital, LLC on September 12, 2025.
This agreement provides a secured term loan of up to $2.0 million for working capital and general corporate purposes, bearing an interest rate of 10.0% per annum.
The loan includes an exit fee of $200,000 (10% of the original principal) and matures on the earlier of receiving $2.4 million from a Qualified Financing or September 14, 2026.
In connection with this new agreement, the company paid off and terminated a prior $2.0 million loan agreement with Banc of California on the same date.